We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Angelman Syndrome Natural History Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04507997
Recruitment Status : Recruiting
First Posted : August 11, 2020
Last Update Posted : November 25, 2022
Sponsor:
Collaborators:
University of California, San Diego
Angelman Syndrome Biomarker & Outcome Measure Consortium (A-BOM)
Food and Drug Administration (FDA)
Canadian Angelman Syndrome Society
Foundation for Angelman Syndrome Therapeutics Canada
Foundation for Angelman Syndrome Therapeutics
Angelman Syndrome Foundation, Inc.
Information provided by (Responsible Party):
Wen-Hann Tan, Boston Children's Hospital

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The goal of this study is to conduct a prospective, longitudinal natural history study of children and adults with Angelman Syndrome using investigator-observed and parent-reported outcome measures to obtain data that will be useful for future clinical trials.

Condition or disease
Angelman Syndrome

Detailed Description:
The overall goal is to increase our understanding of the long-term natural history of Angelman syndrome and obtain Angelman-specific norms for outcome measures that can be used in clinical trials, ultimately improving the care of individuals with Angelman syndrome.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 300 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Angelman Syndrome Natural History Study
Actual Study Start Date : August 1, 2018
Estimated Primary Completion Date : August 2025
Estimated Study Completion Date : August 2025

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Medical History [ Time Frame: Through study completion, an average of 1 year ]
    Includes various medical complications, including seizure history

  2. Developmental History [ Time Frame: Through study completion, an average of 1 year ]
    Developmental milestones in all domains


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All individuals with a molecular diagnosis of Angelman syndrome
Criteria

Inclusion Criteria:

  • Molecular diagnosis of Angelman syndrome

Exclusion Criteria:

  • Presence of another condition, unrelated to Angelman syndrome, that affects neurodevelopment
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04507997


Contacts
Layout table for location contacts
Contact: Wen-Hann Tan, BMBS 617-355 6394 wen-hann.tan@childrens.harvard.edu
Contact: Katherine ("Katie") Anderson, BA 617-919-6008 Katherine.Anderson@childrens.harvard.edu

Locations
Layout table for location information
United States, California
Rady Children's Hospital, San Diego Recruiting
San Diego, California, United States, 92123
Contact: Rachel Winograd, BSN    858-966-8453    rwinograd@rchsd.org   
Principal Investigator: Lynne M. Bird, MD         
United States, Colorado
Children's Hospital Colorado Recruiting
Aurora, Colorado, United States, 80045
Contact: Jessica Duis, MD    720-777-1234    JESSICA.DUIS@cuanschutz.edu   
Principal Investigator: Jessica Duis, MD         
United States, Georgia
Emory Clinic Genetics Recruiting
Atlanta, Georgia, United States, 30322
Contact: Hannah Davis    404-778-8421      
Contact       hannah.k.davis@emory.edu   
Principal Investigator: Amy L. Talboy, MD         
United States, Illinois
Rush University Children's Hospital Recruiting
Chicago, Illinois, United States, 60612
Contact: Kathryn Kudlacz    312-563-9473    Kathryn_L_kudlacz@rush.edu   
Principal Investigator: Cesar Ochoa, MD, MPH         
United States, Massachusetts
Boston Children's Hospital Recruiting
Boston, Massachusetts, United States, 02115
Contact: Wen-Hann Tan, BMBS       wen-hann.tan@childrens.harvard.edu   
Contact: Lotus Lichty, BA    617-919-2536    Lotus.Lichty@childrens.harvard.edu   
United States, North Carolina
The Carolina Institute for Developmental Disabilities Recruiting
Carrboro, North Carolina, United States, 27510
Contact: Margaret DeRamus, MS, CCC-SLP    919-966-5171    margaret.deramus@cidd.unc.edu   
Principal Investigator: Margaret DeRamus, MS, CCC-SLP         
United States, Tennessee
Monroe Carell Jr. Children's Hospital at Vanderbilt Recruiting
Nashville, Tennessee, United States, 37232
Contact: Alexis Calvert, MPH    615-875-8513    alexis.calvert@vumc.org   
Principal Investigator: Robert Carson, MD, PhD         
Canada, Alberta
Alberta Children's Hospital Recruiting
Calgary, Alberta, Canada
Contact: Billie Au, MD, PhD    403-955-7246    Ping-Yee.Au@albertahealthservices.ca   
Principal Investigator: Billie (Ping-Yee) Au, MD, PhD         
Canada, British Columbia
BC Children's Hospital Recruiting
Vancouver, British Columbia, Canada
Contact: Inderpal Gill    604-875-2345 ext 6834    inderpal.gill@cw.bc.ca   
Principal Investigator: Cyrus Boelman, MD         
Canada, Ontario
Children's Hospital of Eastern Ontario Recruiting
Ottawa, Ontario, Canada
Contact: Ioana Moldovan, MD, MSc    613-737-7600 ext 2438    IMoldovan@cheo.on.ca   
Principal Investigator: Erick Sell, MD         
Sponsors and Collaborators
Boston Children's Hospital
University of California, San Diego
Angelman Syndrome Biomarker & Outcome Measure Consortium (A-BOM)
Food and Drug Administration (FDA)
Canadian Angelman Syndrome Society
Foundation for Angelman Syndrome Therapeutics Canada
Foundation for Angelman Syndrome Therapeutics
Angelman Syndrome Foundation, Inc.
Investigators
Layout table for investigator information
Study Chair: Wen-Hann Tan, BMBS Boston Children's Hospital
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Wen-Hann Tan, Attending Physician in Genetics, Boston Children's Hospital
ClinicalTrials.gov Identifier: NCT04507997    
Other Study ID Numbers: IRB-P00025249
First Posted: August 11, 2020    Key Record Dates
Last Update Posted: November 25, 2022
Last Verified: November 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Wen-Hann Tan, Boston Children's Hospital:
Angelman syndrome
Additional relevant MeSH terms:
Layout table for MeSH terms
Angelman Syndrome
Syndrome
Disease
Pathologic Processes
Movement Disorders
Central Nervous System Diseases
 Nervous System Diseases
Abnormalities, Multiple
Congenital Abnormalities
Chromosome Disorders
Genetic Diseases, Inborn